Surrozen prices $60M stock offering to fund eye-disease pipeline
What's the deal? Surrozen, a South San Francisco biotechnology company, has priced a $60 million underwritten offering of common stock, selling 1,894,540 shares at $31.67 each. The post-IPO equity raise drew Access BiotechnologyDealroom has a profile for this one. Try Dealroom →, Boxer Capital Management, Perceptive Advisors, RTW InvestmentsDealroom has a profile for this one. Try Dealroom →, and Venrock Healthcare Capital PartnersDealroom has a profile for this one. Try Dealroom →, among other life sciences investors. The Nasdaq-listed company expects the offering to close on or about November 16, 2026.
What's the endgame? Surrozen develops Wnt-based biologics to treat sight-threatening eye conditions. The money adds to funding for its lead program, SZN-8141, which recently entered clinical testing for diabetic macular edema.
Why now? The raise caps a busy financing stretch. Surrozen closed a $95.1 million tranche of a 2025 private placement in October and raised another $29.8 million net through an at-the-market program that month, pushing pro forma cash to roughly $220 million.
With warrant proceeds, that cash was expected to extend runway into 2029 — so the new offering looks aimed at strengthening an already solid balance sheet rather than plugging a gap.
What could go wrong? Selling 1.9 million new shares adds dilution, and the clinical payoff is years out. Surrozen dosed the first patient in its Phase 1b study and plans a larger Phase 2a trial, with initial Phase 1b data expected in the second half of 2027.
Morgan Stanley, Guggenheim SecuritiesDealroom has a profile for this one. Try Dealroom →, and CantorDealroom has a profile for this one. Try Dealroom → acted as joint book-running managers for the offering.
The signal: The round size stands out for a small-cap biotech, and the roster of specialist healthcare investors signals continued conviction in Wnt-based ophthalmology despite a long wait for clinical evidence.
Read more: Business Insider
Image credit: Generated with Gemini
